This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teicher, B. A. Articles by Sartorelli, A. C. Search for Related Content PubMed PubMed Citation Articles by Teicher, B. A. Articles by Sartorelli, A. C.

Classification of Antineoplastic Agents by their Selective Toxicities toward Oxygenated and Hypoxic Tumor Cells¹

Department of Pharmacology and Developmental Therapeutics Program, Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510

The cytotoxicities of a number of antineoplastic agents to oxygenated and hypoxic EMT6 mouse mammary tumor cells in culture were examined. Based on the relative sensitivities of cells under aerobic and hypoxic conditions, drugs were placed into three categories. Drugs that were preferentially toxic to cells under oxygenated conditions were classified as type 1 agents; this group includes bleomycin, procarbazine, streptonigrin, actinomycin D, and vincristine. Type 2 agents were those preferentially toxic to cells under hypoxic conditions. These include mitomycin C and Adriamycin. On the basis of other published reports, the glucose analogs, 5-thio-D-glucose and 2-deoxy-D-glucose, and the radiosensitizers, misonidazole and metronidazole, can also be placed in this category. Several antineoplastic agents showed no major preferential toxicity to cells under the conditions of oxygenation or hypoxia used in these experiments and were placed in a third class. This group (type 3) includes 1,3-bis(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, cis-diamminedichloroplatinum(II), 5-fluorouracil, and methotrexate. The success of many combination chemotherapy and combined modality treatments may be due to their ability to kill both the hypoxic and aerobic cell populations of solid tumors. Future chemotherapeutic regimens for the treatment of solid tumors should include agents and modalities directed toward the hypoxic cell population of the tumor, as well as toward the proliferating and nonproliferating tumor cell compartments; a therapeutic approach to the selection of antineoplastic agents for use in combination based upon physiological considerations of the architecture of solid tumors is presented.

¹ This research was supported in part by USPHS Grants CA-02817 and CA-16359 from the National Cancer Institute and a grant from the Bristol-Myers Company.

² Recipient of a postdoctoral fellowship (CA-06365) from the National Cancer Institute. To whom requests for reprints should be addressed.

Received 3/17/80. Accepted 9/23/80.

This article has been cited by other articles:

				C. Verhoef, J. H. W. deWilt, F. Brunstein, A. W. K. S. Marinelli, B. vanEtten, M. Vermaas, G. Guetens, G. de Boeck, E. A. de Bruijn, and A. M. M. Eggermont Isolated Hypoxic Hepatic Perfusion with Retrograde Outflow in Patients with Irresectable Liver Metastases; A New Simplified Technique in Isolated Hepatic Perfusion Ann. Surg. Oncol., May 1, 2008; 15(5): 1367 - 1374. [Abstract] [Full Text] [PDF]

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				D. Generali, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, S. Wigfield, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al. Hypoxia-Inducible Factor-1{alpha} Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4562 - 4568. [Abstract] [Full Text] [PDF]

				E. T. Donnelly, Y. Liu, and S. Rockwell Efaproxiral (RSR13) Plus Oxygen Breathing Increases the Therapeutic Ratio of Carboplatin in EMT6 Mouse Mammary Tumors. Experimental Biology and Medicine, March 1, 2006; 231(3): 317 - 321. [Abstract] [Full Text] [PDF]

				A. G. Taghian, R. Abi-Raad, S. I. Assaad, A. Casty, M. Ancukiewicz, E. Yeh, P. Molokhia, K. Attia, T. Sullivan, I. Kuter, et al. Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications J. Clin. Oncol., March 20, 2005; 23(9): 1951 - 1961. [Abstract] [Full Text] [PDF]

				A. M. Samuni, U. Kasid, E. Y. Chuang, S. Suy, W. DeGraff, M. C. Krishna, A. Russo, and J. B. Mitchell Effects of Hypoxia on Radiation-Responsive Stress-Activated Protein Kinase, p53, and Caspase 3 Signals in TK6 Human Lymphoblastoid Cells Cancer Res., January 15, 2005; 65(2): 579 - 586. [Abstract] [Full Text] [PDF]

				H. Kobayashi, K. Reijnders, S. English, A. T. Yordanov, D. E. Milenic, A. L. Sowers, D. Citrin, M. C. Krishna, T. A. Waldmann, J. B. Mitchell, et al. Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation Clin. Cancer Res., November 15, 2004; 10(22): 7712 - 7720. [Abstract] [Full Text] [PDF]

				L. Harrison and K. Blackwell Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? Oncologist, November 1, 2004; 9(suppl_5): 31 - 40. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, M. W. Dewhirst, V. Liotcheva, S. Snyder, G. Broadwater, R. Bentley, A. Lal, G. Riggins, S. Anderson, J. Vredenburgh, et al. HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors Clin. Cancer Res., June 15, 2004; 10(12): 4083 - 4088. [Abstract] [Full Text] [PDF]

				B. van Etten, F. Brunstein, M. G. A. van IJken, A. W. K. S. Marinelli, C. Verhoef, J. R. M. van der Sijp, G. Guetens, G. de Boeck, E. A. de Bruijn, J. H. W. de Wilt, et al. Isolated Hypoxic Hepatic Perfusion With Orthograde or Retrograde Flow in Patients With Irresectable Liver Metastases Using Percutaneous Balloon Catheter Techniques: A Phase I and II Study Ann. Surg. Oncol., June 1, 2004; 11(6): 598 - 605. [Abstract] [Full Text] [PDF]

				B M Seddon and P Workman The role of functional and molecular imaging in cancer drug discovery and development Br. J. Radiol., December 1, 2003; 76(suppl_2): S128 - S138. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, J. P. Kirkpatrick, S. A. Snyder, G. Broadwater, F. Farrell, L. Jolliffe, D. M. Brizel, and M. W. Dewhirst Human Recombinant Erythropoietin Significantly Improves Tumor Oxygenation Independent of Its Effects on Hemoglobin Cancer Res., October 1, 2003; 63(19): 6162 - 6165. [Abstract] [Full Text] [PDF]

				T Wakasa, N Kawai, Y Yanagi, Y Hayase, and K Kishi A study of hypoxic cell radiosensitizer applied to Ehrlich ascite tumour: a comparison of FC43 emulsion and pentoxyfilline Br. J. Radiol., November 1, 2002; 75(899): 909 - 912. [Abstract] [Full Text] [PDF]

				J. Hofland, R. Tenbrinck, M. G. A. van IJken, C. H. J. van Eijck, A. M. M. Eggermont, and W. Erdmann Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy{dagger} Br. J. Anaesth., February 1, 2002; 88(2): 193 - 198. [Abstract] [Full Text] [PDF]

				R.-L. Hong, L.-L. Ting, J.-Y. Ko, M.-M. Hsu, T.-S. Sheen, P.-J. Lou, C.-C. Wang, N.-N. Chung, and L. T. Lui Induction Chemotherapy With Mitomycin, Epirubicin, Cisplatin, Fluorouracil, and Leucovorin Followed by Radiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., December 1, 2001; 19(23): 4305 - 4313. [Abstract] [Full Text]

				M. Hockel and P. Vaupel Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects J Natl Cancer Inst, February 21, 2001; 93(4): 266 - 276. [Abstract] [Full Text] [PDF]

				O. Thews, D. K. Kelleher, and P. Vaupel Erythropoietin Restores the Anemia-induced Reduction in Cyclophosphamide Cytotoxicity in Rat Tumors Cancer Res., February 1, 2001; 61(4): 1358 - 1361. [Abstract] [Full Text]

				S. Guadagni, G. Fiorentini, G. Palumbo, M. Valenti, F. Russo, M. Cantore, M. Deraco, M. Vaglini, and G. Amicucci Hypoxic Pelvic Perfusion With Mitomycin C Using a Simplified Balloon-Occlusion Technique in the Treatment of Patients With Unresectable Locally Recurrent Rectal Cancer Arch Surg, January 1, 2001; 136(1): 105 - 112. [Abstract] [Full Text] [PDF]

				N. Denko, C. Schindler, A. Koong, K. Laderoute, C. Green, and A. Giaccia Epigenetic Regulation of Gene Expression in Cervical Cancer Cells by the Tumor Microenvironment Clin. Cancer Res., February 1, 2000; 6(2): 480 - 487. [Abstract] [Full Text]

				K. Kishi, M. Matsunaka, M. Sato, T. Sonomura, M. Sakurane, and K. Uede T1 and T2 Lip Cancer: A Superselective Method of Facial Arterial Infusion Therapy-Preliminary Experience Radiology, October 1, 1999; 213(1): 173 - 179. [Abstract] [Full Text]

				C. Schmaltz, P. H. Hardenbergh, A. Wells, and D. E. Fisher Regulation of Proliferation-Survival Decisions during Tumor Cell Hypoxia Mol. Cell. Biol., May 1, 1998; 18(5): 2845 - 2854. [Abstract] [Full Text]

				B. Teicher, T. Herman, S. Holden, Y. Wang, M. Pfeffer, J. Crawford, and E Frei 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo Science, March 23, 1990; 247(4949): 1457 - 1461. [Abstract] [PDF]